Kantsone Ieva, Lucenko Irina, Perevoscikovs Jurijs
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden.
Infectious Diseases Surveillance and Immunisation Unit, Infectious Disease Risk Analysis and Prevention Department, Centre for Disease Prevention and Control, Riga, Latvia.
Euro Surveill. 2016 Dec 1;21(48). doi: 10.2807/1560-7917.ES.2016.21.48.30414.
In 1994, the World Health Organization (WHO) declared the goal of eliminating diphtheria within the WHO European Region by the year 2000. However, in 1990 an epidemic emerged within the Russian Federation and spread to other countries, including Latvia, by 1994. We describe national surveillance and immunisation coverage data in Latvia from 1994 to 2014 and present historical data from 1946. We defined a laboratory-confirmed case as a clinical case in which toxin-producing Corynebacterium diphtheriae, C. ulcerans or C. pseudotuberculosis was isolated. From 1994 to 2014, 1,515 cases were reported, giving an average annual incidence of 3.2 cases per 100,000 inhabitants (range 0.1-14.8), with the highest incidence in age groups 5-19 and 40-49 years (4.4 and 4.3/100,000, respectively); 111 deaths were reported, 83.8% cases were laboratory-confirmed. Most cases occurred in unvaccinated adults. To improve disease control a supplementary immunisation campaign for adults was initiated in 1995, and by the end of 1998 national coverage among adults reached 70%, and reached 77% in 2003, but declined to 59% by 2014. Diphtheria remains a problem in Latvia with continued circulation of toxin-producing strains of C. diphtheriae. We recommend to strengthen immunisation to cover adults, as well as the education of health professionals and a serological survey.
1994年,世界卫生组织(WHO)宣布了到2000年在WHO欧洲区域消除白喉的目标。然而,1990年俄罗斯联邦出现了疫情,并在1994年蔓延至包括拉脱维亚在内的其他国家。我们描述了1994年至2014年拉脱维亚的国家监测和免疫接种覆盖率数据,并呈现了1946年以来的历史数据。我们将实验室确诊病例定义为分离出产毒素的白喉棒状杆菌、溃疡棒状杆菌或假结核棒状杆菌的临床病例。1994年至2014年,共报告了1515例病例,平均年发病率为每10万居民3.2例(范围为0.1 - 14.8),5 - 19岁和40 - 49岁年龄组的发病率最高(分别为4.4和4.3/10万);报告了111例死亡,83.8%的病例为实验室确诊。大多数病例发生在未接种疫苗的成年人中。为改善疾病控制,1995年启动了针对成年人的补充免疫接种活动,到1998年底,成年人的国家覆盖率达到70%,2003年达到77%,但到2014年降至59%。白喉在拉脱维亚仍然是一个问题,产毒素的白喉棒状杆菌菌株仍在持续传播。我们建议加强免疫接种以覆盖成年人,同时加强卫生专业人员的教育并开展血清学调查。